FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

General Information

Summary FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in participants with advanced solid tumors.
Clinical trials phase Phase 1
Start date (estimated) 2019-02-15
End date (estimated) 2022-11-15
Clinical feature
Label Advanced Malignant Solid Neoplasm
Link http://purl.obolibrary.org/obo/NCIT_C129707
Description A malignant solid neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.

Administrative Information

NCT number NCT03841110
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03841110
Other study identifiers
Name FT500-101
Source weblink https://clinicaltrials.gov/ct2/show/NCT03841110
Public contact
Email clinical@fatetherapeutics.com
Public email clinical@fatetherapeutics.com
First name Rebecca
Last name Reynolds
Phone +1 (0)858-875-1800
United States
Sponsors Fate Therapeutics


Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Completed
Estimated number of participants 37